SCHEMBL1950816

SCHEMBL1950816

O=C1c2ccc(Br)cc2CCN1c1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC11A2 P49281 1/20 0.56
AOC3 Q16853 3/20 0.54
CRBN Q96SW2 1/20 0.49
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PARP1 P09874 1/20 0.43
ROCK1 Q13464 1/20 0.43
PARP10 Q53GL7 1/20 0.42
PARP11 Q9NR21 1/20 0.42
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951636 0.85 AOC3 (0.58) SLC11A2AOC3CRBNCYP11B1CYP11B2
SCHEMBL29438688 0.84 AOC3 (0.57) SLC11A2AOC3CRBNCYP11B1CYP11B2
SCHEMBL22725969 0.84 AOC3 (0.57) SLC11A2AOC3CRBNCYP11B1CYP11B2
SCHEMBL1948878 0.84 AOC3 (0.54) SLC11A2AOC3CRBNCYP11B1CYP11B2
SCHEMBL29163638 0.83 CRBN (0.56) SLC11A2AOC3CRBNGRIN2DGRIN3B
SCHEMBL19694558 0.82 AOC3 (0.55) SLC11A2AOC3CRBNCYP11B1CYP11B2
SCHEMBL22725970 0.81 AOC3 (0.62) SLC11A2AOC3CRBNPARP1MEN1
SCHEMBL29438703 0.81 AOC3 (0.62) SLC11A2AOC3CRBNPARP1MEN1
SCHEMBL19695036 0.81 AOC3 (0.57) SLC11A2AOC3CRBNCYP11B1CYP11B2
SCHEMBL24503162 0.80 AOC3 (0.50) SLC11A2AOC3CRBNCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168966-B1 BICYCLOANILINE DERIVATIVE MSD KK (JP) 2016-09-28 EP disclosed
EP-2168966-B1 BICYCLOANILINE DERIVATIVE MSD KK (JP) 2016-09-28 EP disclosed
US-8436004-B2 Bicycloaniline derivative MSD K.K. (JP) 2013-05-07 US disclosed
US-8436004-B2 Bicycloaniline derivative MSD K.K. (JP) 2013-05-07 US disclosed
US-8436004-B2 Bicycloaniline derivative MSD K.K. (JP) 2013-05-07 US disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
EP-2168966-A1 BICYCLOANILINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed
EP-2168966-A1 BICYCLOANILINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135601-A1 BICYCLOANILINE DERIVATIVE WEE1, WEE2, CCNK SLC11A2 3520/4885AOC3 1326/4885CRBN 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.